{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:44:38Z","timestamp":1774007078181,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00277-016-2648-4","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:06:47Z","timestamp":1459296407000},"page":"893-899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial"],"prefix":"10.1007","volume":"95","author":[{"name":"on behalf of the GELTAMO group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gonz\u00e1lez-Barca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Canales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Ferreiro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ferrer-Bordes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Garc\u00eda-Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"S\u00e1nchez-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Garc\u00eda-Frade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pe\u00f1alver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Bello-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"key":"2648_CR1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","volume":"124","author":"MB M\u00f8ller","year":"2004","unstructured":"M\u00f8ller MB, Pedersen NT, Christensen BE (2004) Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation\u2014a population-based study of 1575 cases. Br J Haematol 124:151\u2013159","journal-title":"Br J Haematol"},{"key":"2648_CR2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C et al (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87:146\u2013171","journal-title":"Crit Rev Oncol Hematol"},{"key":"2648_CR3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"2648_CR4","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van HA, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 23:4117\u20134126","journal-title":"J Clin Oncol"},{"key":"2648_CR5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"key":"2648_CR6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A et al (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381:1817\u20131826","journal-title":"Lancet"},{"key":"2648_CR7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.hoc.2005.05.003","volume":"19","author":"P Bierman","year":"2005","unstructured":"Bierman P, Giglio P (2005) Diagnosis and treatment of central nervous system involvement in non-Hodgkin\u2019s lymphoma. Hematol Oncol Clin North Am 19:597\u2013609","journal-title":"Hematol Oncol Clin North Am"},{"key":"2648_CR8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","volume":"105","author":"U Hegde","year":"2005","unstructured":"Hegde U, Filie A, Little RF et al (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496\u2013502","journal-title":"Blood"},{"key":"2648_CR9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol 18:149\u2013157","journal-title":"Ann Oncol"},{"key":"2648_CR10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/annonc\/mdm073","volume":"18","author":"M Bjorkholm","year":"2007","unstructured":"Bjorkholm M, Hagberg H, Holte H et al (2007) Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 18:1085\u20131089","journal-title":"Ann Oncol"},{"key":"2648_CR11","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"V Boehme","year":"2009","unstructured":"Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:3896\u20133902","journal-title":"Blood"},{"key":"2648_CR12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-009-0289-2","volume":"89","author":"Y Shimazu","year":"2009","unstructured":"Shimazu Y, Notohara K, Ueda Y (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 89:577\u2013583","journal-title":"Int J Hematol"},{"key":"2648_CR13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","volume":"27","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014the Southwest Oncology Group. J Clin Oncol 27:114\u2013119","journal-title":"J Clin Oncol"},{"key":"2648_CR14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/CCO.0b013e3283499c7c","volume":"23","author":"A Korfel","year":"2011","unstructured":"Korfel A (2011) Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol 23:436\u2013440","journal-title":"Curr Opin Oncol"},{"key":"2648_CR15","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","volume":"86","author":"J Cortes","year":"1995","unstructured":"Cortes J, O\u2019Brien S, Pierce S, Keating MJ, Freireich EJ, Kantarjian H (1995) The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86:2091\u20132097","journal-title":"Blood"},{"key":"2648_CR16","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","volume":"104","author":"K Blum","year":"2004","unstructured":"Blum K, Lozanski G, Byrd J (2004) Adult Burkitt leukemia and lymphoma. Blood 104:3009\u20133020","journal-title":"Blood"},{"key":"2648_CR17","unstructured":"National Comprehensive Cancer Network (2010) National Comprehensive Cancer Network guidelines for treatment of cancer by site: non-Hodgkin\u2019s lymphoma. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed Dec 19 2014"},{"key":"2648_CR18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/annonc\/mdq203","volume":"21","author":"H Tilly","year":"2010","unstructured":"Tilly H, Dreyling M (2010) Diffuse large B-cell non-Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:172\u2013174","journal-title":"Ann Oncol"},{"key":"2648_CR19","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, Thomas D, Cortes J, Kantarjian HM, O\u2019Brien S (2010) Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116:2290\u20132300","journal-title":"Cancer"},{"key":"2648_CR20","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","volume":"86","author":"J Cortes","year":"1995","unstructured":"Cortes J, O\u2019Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM (1995) The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86:2091\u20132097","journal-title":"Blood"},{"key":"2648_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/14737175.4.4.S19","volume":"4","author":"L DeAngelis","year":"2004","unstructured":"DeAngelis L (2004) Primary CNS lymphoma: is there a role for prophylaxis against lymphomatous meningitis? Expert Rev Neurother 4:19\u201321","journal-title":"Expert Rev Neurother"},{"key":"2648_CR22","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1200\/JCO.1993.11.11.2186","volume":"11","author":"S Kim","year":"1993","unstructured":"Kim S, Chatelut E, Kim J et al (1993) Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11:2186\u20132193","journal-title":"J Clin Oncol"},{"key":"2648_CR23","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","volume":"17","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110\u20133116","journal-title":"J Clin Oncol"},{"key":"2648_CR24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.critrevonc.2010.12.003","volume":"79","author":"S Cortelazzo","year":"2011","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D (2011) Lymphoblastic lymphoma. Crit Rev Oncol Hematol 79:330\u2013343","journal-title":"Crit Rev Oncol Hematol"},{"key":"2648_CR25","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.1995.13.10.2656","volume":"13","author":"AC Aisenberg","year":"1995","unstructured":"Aisenberg AC (1995) Coherent view of non-Hodgkin\u2019s lymphoma. J Clin Oncol 13:2656\u20132675","journal-title":"J Clin Oncol"},{"key":"2648_CR26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:1244\u20131253","journal-title":"J Clin Oncol"},{"key":"2648_CR27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","volume":"159","author":"HR Guirguis","year":"2012","unstructured":"Guirguis HR, Cheung MC, Mahrous M et al (2012) Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 159:39\u201349","journal-title":"Br J Haematol"},{"key":"2648_CR28","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","volume":"13","author":"A Hollender","year":"2002","unstructured":"Hollender A, Kvaloy S, Nome O et al (2002) Central nervous system involvement following diagnosis of non-Hodgkin lymphoma: a risk model. Ann Oncol 13:1099\u20131107","journal-title":"Ann Oncol"},{"key":"2648_CR29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/annonc\/mdr440","volume":"23","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Zynalova S, Galss B et al (2012) CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 23:1267\u20131273","journal-title":"Ann Oncol"},{"key":"2648_CR30","first-page":"96","volume":"31","author":"N Schmitz","year":"2013","unstructured":"Schmitz N, Zeylaniva S, Nikelsen M et al (2013) A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematol Oncol 31:96\u2013150","journal-title":"Hematol Oncol"},{"key":"2648_CR31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood.V124.21.394.394","volume":"124","author":"KJ Savage","year":"2014","unstructured":"Savage KJ, Samira Zeynalova S, Kansara RR et al (2014) Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-Cell lymphoma. Blood 124:394","journal-title":"Blood"},{"key":"2648_CR32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","volume":"21","author":"E Zucca","year":"2003","unstructured":"Zucca E, Conconi A, Mughal TI et al (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20\u201327","journal-title":"J Clin Oncol"},{"key":"2648_CR33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjh.12753","volume":"165","author":"PJ Hosein","year":"2014","unstructured":"Hosein PJ, Maragulia JC, Salzberg MP et al (2014) A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol 165:358\u2013363","journal-title":"Br J Haematol"},{"key":"2648_CR34","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2011.041277","volume":"96","author":"D Villa","year":"2011","unstructured":"Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ (2011) Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 96:1002\u20131007","journal-title":"Haematologica"},{"key":"2648_CR35","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2013.869326","volume":"55","author":"CD Fletcher","year":"2014","unstructured":"Fletcher CD, Kahl BS (2014) Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risk and prevention strategies in the post-rituximab era. Leuk Lymphoma 55:2228\u20132240","journal-title":"Leuk Lymphoma"},{"key":"2648_CR36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bjh.13194","volume":"168","author":"AJ Ferreri","year":"2015","unstructured":"Ferreri AJ, Bruno-Ventre M, Donadoni G et al (2015) Risk tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 168:654\u2013662","journal-title":"Br J Haematol"},{"key":"2648_CR37","doi-asserted-by":"crossref","unstructured":"Sancho JM, Ribera, JM (2015) Central nervous system relapse in diffuse large B-cell lymphoma: risk factors. Med Clin (Barc)","DOI":"10.1016\/j.medcle.2014.12.003"},{"key":"2648_CR38","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA et al (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:4283\u20134290","journal-title":"Cancer"},{"key":"2648_CR39","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C R\u00e9cher","year":"2011","unstructured":"R\u00e9cher C, Coiffier B, Haioun C et al (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378:1858\u20131867","journal-title":"Lancet"},{"key":"2648_CR40","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/annonc\/mds621","volume":"24","author":"H Holte","year":"2013","unstructured":"Holte H, Lepp\u00e4 S, Bj\u00f6rkholm M et al (2013) Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic lymphoma group study. Ann Oncol 24:1385\u20131392","journal-title":"Ann Oncol"},{"key":"2648_CR41","first-page":"10","volume":"6","author":"SB Howell","year":"2003","unstructured":"Howell SB (2003) Liposomal cytarabine for the treatment of lymphomatous meningitis. Biol Ther Lymphoma 6:10\u201314","journal-title":"Biol Ther Lymphoma"},{"key":"2648_CR42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1517\/14656566.9.2.301","volume":"9","author":"M Benesch","year":"2008","unstructured":"Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 9:301\u2013309","journal-title":"Expert Opin Pharmacother"},{"key":"2648_CR43","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/cncr.11449","volume":"97","author":"BF Cole","year":"2003","unstructured":"Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI (2003) Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 97:3053\u20133060","journal-title":"Cancer"},{"key":"2648_CR44","volume-title":"DepoCyt (liposomal cytarabine) prescribing information","author":"Pacira Pharmaceuticals","year":"2007","unstructured":"Pacira Pharmaceuticals (2007) DepoCyt (liposomal cytarabine) prescribing information. Pacira Pharmaceuticals, San Diego"},{"key":"2648_CR45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2010.028092","volume":"96","author":"N G\u00f6kbuget","year":"2011","unstructured":"G\u00f6kbuget N, Hartog CM, Bassan R et al (2011) Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 96:238\u2013244","journal-title":"Haematologica"},{"key":"2648_CR46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","volume":"156","author":"G Corazzelli","year":"2012","unstructured":"Corazzelli G, Frigeri F, Russo F et al (2012) RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adultBurkitt lymphoma and \u2018unclassifiable\u2019 highly aggressive B-cell lymphoma. Br J Haematol 156:234\u2013244","journal-title":"Br J Haematol"},{"key":"2648_CR47","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00277-015-2475-z","volume":"94","author":"A Segot","year":"2015","unstructured":"Segot A, Raffoux E, Lengline E et al (2015) Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia\/lymphoma. Ann Hematol 94:1859\u20131863","journal-title":"Ann Hematol"},{"key":"2648_CR48","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, O\u2019Brien S, Kantarjian H et al (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214\u20133218","journal-title":"Blood"},{"key":"2648_CR49","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cncr.24204","volume":"115","author":"JA Garcia-Marco","year":"2009","unstructured":"Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115:1892\u20131898","journal-title":"Cancer"},{"key":"2648_CR50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.20452\/pamw.1968","volume":"123","author":"K Krawczyk","year":"2013","unstructured":"Krawczyk K, Jurczak W, D\u0142ugosz-Danecka M et al (2013) Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. Pol Arch Med Wewn 123:589\u2013595","journal-title":"Pol Arch Med Wewn"},{"key":"2648_CR51","first-page":"s1","volume":"99","author":"A Fuente De la","year":"2014","unstructured":"De la Fuente A, Olave M, Pe\u00f1alver FJ et al (2014) DEPO-ITV: a new scenario with intrathecal and intravenous dexamethasone to prevent chemical arachnoiditis related with liposomal cytarabine. Haematologica 99:s1","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2648-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2648-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T01:07:40Z","timestamp":1748826460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2648-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2648"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2648-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}